New Releases from NCBI BookshelfLorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer.Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer.
Post Content
The United Kingdom is experiencing worrying trends in population health. Policy needs to shift ‘upstream’ to address fundamental causes. Universal
Vulnerability is a fundamental aspect of existence, giving rise to the need for care in various forms. Yet we are
Post Content
Surgical outcomes are worse in people with diabetes, in part, because of the effects of hyperglycaemia, obesity and other comorbidities.